CN102209730B - 抗cxcr4抗体及其用于治疗癌症的用途 - Google Patents

抗cxcr4抗体及其用于治疗癌症的用途 Download PDF

Info

Publication number
CN102209730B
CN102209730B CN200980144491.4A CN200980144491A CN102209730B CN 102209730 B CN102209730 B CN 102209730B CN 200980144491 A CN200980144491 A CN 200980144491A CN 102209730 B CN102209730 B CN 102209730B
Authority
CN
China
Prior art keywords
antibody
cxcr4
cdr
sequence seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980144491.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102209730A (zh
Inventor
C·克林格-阿穆
V·格勒尼耶-科萨内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN102209730A publication Critical patent/CN102209730A/zh
Application granted granted Critical
Publication of CN102209730B publication Critical patent/CN102209730B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
CN200980144491.4A 2008-10-01 2009-10-01 抗cxcr4抗体及其用于治疗癌症的用途 Expired - Fee Related CN102209730B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13677208P 2008-10-01 2008-10-01
EP08305631A EP2172485A1 (en) 2008-10-01 2008-10-01 Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP08305631.7 2008-10-01
US61/136,772 2008-10-01
US17374309P 2009-04-29 2009-04-29
US61/173,743 2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en) 2008-10-01 2009-10-01 Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (2)

Publication Number Publication Date
CN102209730A CN102209730A (zh) 2011-10-05
CN102209730B true CN102209730B (zh) 2014-11-05

Family

ID=40361774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980144491.4A Expired - Fee Related CN102209730B (zh) 2008-10-01 2009-10-01 抗cxcr4抗体及其用于治疗癌症的用途

Country Status (29)

Country Link
US (4) US8557964B2 (ru)
EP (2) EP2172485A1 (ru)
JP (1) JP5723279B2 (ru)
KR (1) KR101671039B1 (ru)
CN (1) CN102209730B (ru)
AR (1) AR073748A1 (ru)
AU (1) AU2009299787B2 (ru)
BR (1) BRPI0920531A2 (ru)
CA (1) CA2738782C (ru)
CL (1) CL2011000730A1 (ru)
CY (1) CY1115572T1 (ru)
DK (1) DK2342233T3 (ru)
ES (1) ES2503732T3 (ru)
GE (1) GEP20146084B (ru)
HK (1) HK1163119A1 (ru)
HR (1) HRP20140899T1 (ru)
IL (1) IL212066A (ru)
MA (1) MA32928B1 (ru)
MX (1) MX2011003509A (ru)
NZ (1) NZ592363A (ru)
PL (1) PL2342233T3 (ru)
PT (1) PT2342233E (ru)
RS (1) RS53578B1 (ru)
RU (1) RU2573897C2 (ru)
SI (1) SI2342233T1 (ru)
TW (1) TWI469792B (ru)
UA (1) UA102867C2 (ru)
WO (1) WO2010037831A1 (ru)
ZA (1) ZA201102969B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
AU2011322508A1 (en) * 2010-10-27 2013-05-02 Pierre Fabre Medicament Antibodies for the treatment of HIV
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) * 2013-04-18 2014-10-21 Bosch Gmbh Robert Thermostat for a hvac.
CN113683695A (zh) * 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
IL305656A (en) 2013-09-23 2023-11-01 Wilson Wolf Mfg Corporation Improved methods for genetic modification in animal cells
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
CA2989144A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
KR20180085736A (ko) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
US10973852B2 (en) 2016-01-25 2021-04-13 Nantcell, Inc. NK cells with altered CXCL12/CXCR4 signaling
JPWO2017203799A1 (ja) * 2016-05-25 2019-02-28 株式会社東芝 エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018143938A1 (en) * 2017-01-31 2018-08-09 Msm Protein Technologies Inc. Anti-cxcr4 antibodies
EP3765519B1 (en) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN112661845B (zh) * 2020-12-25 2022-06-21 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及其应用
CN112521500B (zh) * 2020-12-25 2022-06-24 暨南大学 与cxcr4结合的亲和力成熟结合蛋白及应用
CN117003876A (zh) * 2023-08-31 2023-11-07 恺佧生物科技(上海)有限公司 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004059285A2 (en) * 2002-12-23 2004-07-15 Protein Design Labs, Inc. Tumor killing/tumor regression using cxcr4 antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
WO2006086883A1 (en) * 2005-02-16 2006-08-24 Universite De Montreal Biosensors for monitoring receptor-mediated g-protein activation
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
CN102027015A (zh) * 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004059285A2 (en) * 2002-12-23 2004-07-15 Protein Design Labs, Inc. Tumor killing/tumor regression using cxcr4 antagonists

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
acute *
Alessandro Ottaiano.Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.《Cancer Immunol Immunother》.2005,第54卷摘要，第786页右栏、第788页左栏. *
Anti-CXCR4 Monoclonal Antibodies Recognizing Overlapping;Xavier Carnec;《JOURNAL OF VIROLOGY》;20050228;第79卷(第3期);1930–1933 *
Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers;Yann Percherancier;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20050318;第280卷(第11期);摘要 *
DE&acute *
DE&amp *
FRE&acute *
FRE&amp *
Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells;Alessandro Ottaiano;《Cancer Immunol Immunother》;20051231;第54卷;摘要，第786页右栏、第788页左栏 *
RIC BARIBAUD.Antigenically Distinct Conformations of CXCR4.《JOURNAL OF VIROLOGY》.2001,第75卷(第19期),8957–8967. *
Xavier Carnec.Anti-CXCR4 Monoclonal Antibodies Recognizing Overlapping.《JOURNAL OF VIROLOGY》.2005,第79卷(第3期),1930–1933. *
Yann Percherancier.Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.2005,第280卷(第11期),摘要. *

Also Published As

Publication number Publication date
US8557964B2 (en) 2013-10-15
KR101671039B1 (ko) 2016-11-01
AU2009299787B2 (en) 2015-06-18
AR073748A1 (es) 2010-12-01
PT2342233E (pt) 2014-10-03
RU2573897C2 (ru) 2016-01-27
US20110020218A1 (en) 2011-01-27
CY1115572T1 (el) 2017-01-04
GEP20146084B (en) 2014-05-13
IL212066A (en) 2015-05-31
DK2342233T3 (da) 2014-09-29
IL212066A0 (en) 2011-06-30
SI2342233T1 (sl) 2014-10-30
EP2342233B1 (en) 2014-06-25
CN102209730A (zh) 2011-10-05
JP2012504401A (ja) 2012-02-23
RU2011115559A (ru) 2012-11-10
US20110294156A1 (en) 2011-12-01
TW201018483A (en) 2010-05-16
AU2009299787A2 (en) 2011-06-02
HK1163119A1 (en) 2012-09-07
MX2011003509A (es) 2011-05-02
EP2342233A1 (en) 2011-07-13
CA2738782A1 (en) 2010-04-08
KR20110081229A (ko) 2011-07-13
HRP20140899T1 (hr) 2014-11-07
CL2011000730A1 (es) 2012-02-03
ES2503732T3 (es) 2014-10-07
CA2738782C (en) 2017-11-28
WO2010037831A1 (en) 2010-04-08
RS53578B1 (en) 2015-02-27
AU2009299787A1 (en) 2010-04-08
MA32928B1 (fr) 2012-01-02
US20140050661A1 (en) 2014-02-20
EP2172485A1 (en) 2010-04-07
TWI469792B (zh) 2015-01-21
NZ592363A (en) 2012-08-31
US20110287451A1 (en) 2011-11-24
US9388248B2 (en) 2016-07-12
ZA201102969B (en) 2011-12-28
PL2342233T3 (pl) 2014-11-28
JP5723279B2 (ja) 2015-05-27
UA102867C2 (ru) 2013-08-27
BRPI0920531A2 (pt) 2021-02-23

Similar Documents

Publication Publication Date Title
CN102209730B (zh) 抗cxcr4抗体及其用于治疗癌症的用途
CN102939306B (zh) 用于治疗癌症的人源化抗cxcr4抗体
CN103002916B (zh) 新的抗-cMET抗体
CN102227446B (zh) 抗-cMET抗体
CN101535344B (zh) 新型抗增殖抗体
CN101238149A (zh) 新抗igf-ir抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1163119

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1163119

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141105

Termination date: 20191001